Cheapest GLP-1 in 2026: how to get Wegovy, Zepbound & Ozempic for less

Step 1: exhaust insurance first — it is the cheapest path

If your plan covers weight-loss GLP-1s, a covered copay can be as low as $0-25/month — cheaper than any cash option. The problem is that many commercial plans exclude the obesity indication, and PBM formulary rules (prior authorization, step therapy) create friction even when nominally covered.

Two moves maximize your odds. First, identify your PBM — it, not your insurer name, sets the formulary. Our PBM identifier tool maps your carrier to its PBM and shows the Wegovy/Zepbound coverage stance. Second, if you have established cardiovascular disease plus BMI ≥27, the SELECT-based cardiovascular indication for Wegovy is often easier to get approved than the pure obesity indication.

If denied, appeal. About 40% of well-documented obesity-drug denials reverse on appeal. Our prior-auth letter tool generates a prescriber-ready appeal with the BMI, comorbidity, and prior-lifestyle-attempt documentation payers look for.

• Sources for this section
• KFF — Consumer appeal process research — Kaiser Family Foundation

Step 2: manufacturer cash programs (no insurance needed)

Both makers sell direct-to-patient at roughly half the pharmacy list price, with no insurance and no prior authorization.

Wegovy: $499/month for all doses via NovoCare Pharmacy (Novo Nordisk direct). This is the cash price for self-paying patients, shipped to your door.

Zepbound: $349/month for the 2.5 mg starter vial and $499/month for higher-dose vials via LillyDirect (Eli Lilly direct). The vial presentation (not the auto-injector pen) is what enables the lower price.

These are the best options for a patient who wants brand-name product without insurance. They beat GoodRx retail-coupon prices (~$1,000-1,350/mo) by a wide margin.

• Sources for this section
• NovoCare — Wegovy cost + savings — Novo Nordisk
• LillyDirect — Zepbound self-pay pharmacy — Eli Lilly

Step 3: compounded telehealth — the cheapest ongoing path

Licensed 503A telehealth providers prescribe patient-specific compounded semaglutide or tirzepatide for $99-249/month — the lowest ongoing cost for most people. This is real medication from a state-licensed compounding pharmacy, prescribed by a licensed clinician after a telehealth visit.

The important honesty: after the FDA shortage ended (tirzepatide October 2024, semaglutide February 2025), compounding is legal only as an individualized 503A compound — the pharmacy must document a patient-specific clinical need for a non-commercial formulation. It is not the same as brand-name Wegovy or Zepbound, and quality varies by pharmacy. Choose a provider that uses a reputable, inspected 503A pharmacy and lists the source.

Our vetted-provider directory ranks currently-compliant compounded options. See the compounding retrospective for the full legal + safety picture before choosing this path.

• Sources for this section
• FDA — Compounding and the drug shortage — US FDA

Step 4: manufacturer savings cards (for the insured)

If you have commercial insurance that covers your GLP-1, the manufacturer savings card can reduce your copay further. Novo's WegovyCare and Lilly's Zepbound savings card both lower out-of-pocket cost for eligible commercially-insured patients — sometimes to as little as $0-25/month depending on your plan.

Two limits to know: savings cards exclude government insurance (Medicare, Medicaid, TRICARE) by law, and they have annual maximums. They stack with commercial coverage, not with the cash programs above. If you are commercially insured and covered, the savings card is usually your cheapest path; if you are uninsured or on Medicare, use the cash programs or compounded telehealth instead.

What to avoid: the illegal "research chemical" trap

Search results and social media surface "semaglutide for sale" from sites selling unlicensed powder or vials as "research chemicals not for human consumption," often without any prescription. This is illegal to use, completely unregulated, and dangerous — there is no verification of purity, dose accuracy, sterility, or even that the vial contains semaglutide at all.

The FDA has issued warnings about counterfeit and unapproved semaglutide products. No legitimate cost saving is worth the risk of an unregulated injectable. Every path in this guide involves a licensed prescriber and a licensed pharmacy — that is the line between a real saving and a serious health risk.

• Sources for this section
• FDA — Counterfeit Ozempic (semaglutide) warning — US FDA

Which path is cheapest for you — a quick decision

Insured with weight-loss coverage: use your benefit + a manufacturer savings card. Likely $0-25/mo. Cheapest option.

Insured but weight-loss excluded: appeal first (40% reverse). If denied, compounded telehealth ($99-249/mo) or manufacturer cash ($349-499/mo).

Uninsured, want brand-name: manufacturer cash — Wegovy $499/mo (NovoCare) or Zepbound $349-499/mo (LillyDirect).

Uninsured, want lowest cost: licensed compounded telehealth, $99-249/mo. Individualized 503A compound, not brand product.

On Medicare/Medicaid: savings cards are excluded. Use manufacturer cash or compounded telehealth, and check whether your state Medicaid covers the obesity indication (most do not — see our state Medicaid coverage report).

The real monthly numbers, side by side

List price is a fiction almost nobody pays. Here is what the paths actually cost per month in 2026, cheapest to most expensive. Covered insurance copay: $0-25 (when your plan covers the obesity indication). Licensed compounded semaglutide/tirzepatide via telehealth: $99-249. Zepbound self-pay vials via LillyDirect: $349 (2.5 mg starter) to $499 (higher doses). Wegovy self-pay via NovoCare: $499 flat. GoodRx/retail-coupon brand price: roughly $1,000-1,350. Full cash list price with no discount: $1,000-1,600.

The spread between the cheapest legitimate path ($0-25 covered, or $99 compounded) and the list price ($1,600) is more than 60×. That gap is exactly why it pays to work the list top-down: exhaust insurance, then cash programs, then compounded — rather than defaulting to whatever your pharmacy quotes first.

• Sources for this section
• Glpverdict — 2026 GLP-1 cash price spread (24 sources compared) — Glpverdict Primary-Data Research

The insurance appeal playbook (when you are denied)

About 40% of well-documented obesity-drug denials reverse on appeal, so a denial is a starting point, not the end. The appeal that works includes: documented BMI ≥30, or ≥27 with a named weight-related comorbidity (hypertension, prediabetes, sleep apnea, PCOS, dyslipidemia); evidence of a prior lifestyle-intervention attempt; and a prescriber letter of medical necessity that ties your case to the FDA-approved indication.

Two leverage points many patients miss. First, a formulary exception: if your plan covers one GLP-1 but not the one you were prescribed, your prescriber can request an exception documenting why the covered alternative is unsuitable. Second, the medical-indication route: if you have established cardiovascular disease (Wegovy, SELECT) or obstructive sleep apnea (Zepbound, SURMOUNT-OSA), appealing under that indication is often easier than the pure obesity indication. Our prior-auth letter tool assembles the documentation payers look for.

• Sources for this section
• KFF — Claims denials and appeals in ACA marketplace plans — Kaiser Family Foundation

If you choose compounded: a safety checklist

Compounded is the cheapest ongoing path, but quality varies by pharmacy and the category attracts bad actors — so vet before you buy. A legitimate operation clears every item on this checklist: (1) a real telehealth visit with a licensed prescriber before any prescription; (2) the compound dispensed by a named, state-licensed 503A pharmacy (ask for the name and verify it with the state board of pharmacy); (3) semaglutide or tirzepatide base — not the unapproved salt forms (semaglutide sodium/acetate) the FDA has warned about; (4) clear beyond-use dating and cold-chain shipping; (5) no pressure to buy in bulk or pay in crypto.

Red flags that should stop you cold: no prescription required, "research chemical / not for human consumption" labeling, prices that seem impossibly low, overseas shipping outside a licensed pharmacy, or a website that will not name its pharmacy. Our vetted-provider directory lists currently-compliant compounded options, and the compounding retrospective explains the post-shortage legal picture.

• Sources for this section
• FDA — Medications containing semaglutide marketed for weight loss (compounding safety) — US FDA